Answer
Intravenous atezolizumab has a typical terminal elimination half-life of 27 days, based on a population pharmacokinetic analysis.
Sources for this answer
- Tecentriq 840 mg and 1,200 mg concentrate for solution for infusionRoche Products Limited · emc · SmPC §5.2 Pharmacokinetic properties · Version 44Document updated
Sources checked